Examples of how OncoSim has been used

All cancers

• Long-term projections of cancer incidence and mortality in Canada: The OncoSim All Cancers Model
• Cancer in Canada – Future Projections
• The Economic Burden of Cancer in Canada from a Societal Perspective
• Estimates of future cancer management costs attributable to modifiable risk factors in Canada
• Estimates of future cancer mortality attributable to modifiable risk factors in Canada
• Cancer burden attributable to risk factors

Breast cancer

• The OncoSim-Breast cancer microsimulation model
• The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada
• The Value of All-Cause Mortality as a Metric for Assessing Breast Cancer Screening
• The OncoSim-Breast model reproduces the observed effects of a randomized screening trial
• Potential benefits of reducing breast cancer screening abnormal call rates

Cervical cancer/HPV

• Impact of the COVID-19 pandemic on the incidence and mortality of cervical cancer in Canada. Projections from OncoSim-HPV/Cervical cancer (IPV conference)
• Action plan for the elimination of cervical cancer
• Moving towards the elimination of cervical cancer: modeling the health and economic benefits of increasing HPV vaccine uptake
• Starting cervical cancer screening at 25 years of age: the time has come
• Exploring the health outcomes of various pan-Canadian cervical cancer screening programs using microsimulation modeling
• Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM)
• Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada
• Evaluation of the natural history of cancer of the cervix, implications for prevention. The Cancer Risk Management Model (CRMM) – Human papillomavirus and cervical components

Colorectal cancer

• Potential global loss of life expected due to COVID-19 disruptions to organised colorectal cancer screening
• Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study
• The impact on clinical outcomes and healthcare resources from discontinuing colonoscopy surveillance subsequent to low-risk adenoma removal: A simulation study using the OncoSim-Colorectal model
• Association of Reducing the Recommended Colorectal Cancer Screening Age With Cancer Incidence, Mortality, and Costs in Canada Using OncoSim
• Participatory simulation modeling to inform colorectal cancer screening in a complex remote northern health system: Canada’s Northwest Territories
• The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada
• Simulating Results from Trials of Sigmoidoscopy Screening Using the OncoSim Microsimulation Model
• Projected Effect of Fecal Immunochemical Test Threshold for Colorectal Cancer Screening on Outcomes and Costs for Canada using the OncoSim Microsimulation Model
• Recommendations on screening for colorectal cancer in primary care
• Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada
• Family history-based colorectal cancer screening
• Comparing the health and economic impacts of two screening strategies for colorectal cancer in Canada using the Cancer Risk Management Model (CRMM)

Lung cancer

• Impact of organized lung screening in Canada
• Efficacy of Risk Prediction Models and Thresholds to Select Patients for Lung Cancer Screening
• Estimating the cost effectiveness and clinical impact of adding smoking cessation to an organized CT lung cancer screening program in Canada
• Biennial lung cancer screening in Canada with smoking cessation—outcomes and cost-effectiveness
• Implementing low-dose computer tomography screening for lung cancer in Canada: implications of alternative at-risk populations, screening frequency and duration
• Recommendations on screening for lung cancer
• Cost-effectiveness of lung cancer screening in Canada
• Eligibility for low-dose computerized tomography screening among asbestos-exposed individuals
• Measuring the population impact of introducing stereotactic ablative radiotherapy for stage I non-small cell lung cancer in Canada
• Low dose computed tomography for the screening of lung cancer in adults
• The evaluation of cancer control interventions in lung cancer using the Canadian Cancer Risk Management Model
• Costs and cost-effectiveness of smoking cessation within an organized CT lung cancer screening program
• How in the real world are lung cancer patients treated?
• Lung cancer-related clinical and economic impacts of achieving a 5% smoking rate by 2035 in Canada
• Comparing the health and economic outcomes of opportunistic lung cancer screening vs. organized lung screening using the Cancer Risk Management Model
• Annual vs. biennial lung cancer screening using the Cancer Risk Management Model to fill gaps in evidence

COVID-19 modelling

• Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study
• Impact of the COVID-19 pandemic on FAECAL immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: A comparative modelling study
• The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada

Other

• 2018 Cancer system performance report
• The OncoSim Model: Development and use for better decision-making in Canadian cancer control
• 2017 Cancer system performance report
• Quality and sustainability in cancer control: A system performance report
• Canadian Cancer Risk Management Model: Evaluation of cancer control
• Translating research to inform policy decisions